Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MDH2 | P40926 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28692077 | 0.90 | F7 (0.50) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL11143666 | 0.87 | KDM4E (0.68) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL18589525 | 0.82 | CYP1A2 (0.64) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL30906941 | 0.81 | F7 (0.66) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL30416773 | 0.81 | KDM4E (0.77) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL2974546 | 0.81 | ALDH1A1 (0.62) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL4452877 | 0.81 | KDM4E (0.77) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL4342972 | 0.81 | CYP1A2 (0.62) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL12786892 | 0.81 | CYP1A2 (0.62) | CYP1A2ALDH1A1HPGDMEN1ALOX12 | |
| SCHEMBL2965244 | 0.81 | F7 (0.66) | CYP1A2ALDH1A1HPGDMEN1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498341-B2 | antidiabetic agents; type 2 diabetes | SANOFI AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470706-B2 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| EP-1713804-B1 | CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1720870-B1 | HETEROCYCLICALLY SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-22 | — | — | EP | disclosed |
| CN-1910181-A | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1910182-A | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1910181-A | Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA GMBH (DE) | 2007-02-07 | — | — | CN | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| WO-2005073230-A1 | HETEROCYCLICALLY SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073231-A1 | CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | WO | disclosed |
| US-4404201-A | N-/ /ALKANOYLAMINOALKANOYLAMINO OR AMINOALKANOYL AMINO/-DIHYDRO-OXO-3-QUINOLINYLCARBONYL/- DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4382089-A | Antibacterial amide compounds, compositions thereof and methods of using them | WARNER-LAMBERT COMPANY (US) | 1983-05-03 | — | — | US | disclosed |
| US-4137227-A | BACTERICIDES | STERLING DRUG INC. (US) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182086-A1 | antidiabetic agents; type 2 diabetes | SLC5A2, SLC5A1, SLC2A2 | CYP1A2 37/4885ALDH1A1 365/4885HPGD 436/4885 |
| US-20050182087-A1 | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SLC5A2, QPCT, GLS | CYP1A2 35/4885ALDH1A1 623/4885HPGD 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.